| Study |
Reference |
|
Al Khalaf - Beta-blockers (Controls unexposed, disease free), 2022
|
Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558
|
|
Al Khalaf - Beta-blockers (Controls unexposed, sick), 2022
|
Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558
|
|
Albertini - Beta-blockers, 2023
|
Albertini Assessment of Severity of Long QT Syndrome Phenotype and Risk of Fetal Death. J Am Heart Assoc 2023; 12:e029407
|
|
Baard - Beta-blockers, 2020
|
Baard The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr 2020; 31:136-141
|
|
Bateman - Beta-blockers, 2016
|
Bateman Late Pregnancy Beta Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics 2016; 138:
|
|
Bateman_Nordic - Beta-blockers, 2018
|
Bateman Beta-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study. Ann Intern Med 2018; 169:665-673
|
|
Bateman_USMAX - Beta-blockers, 2018
|
Bateman Beta-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study. Ann Intern Med 2018; 169:665-673
|
|
Bayliss - Atenolol, 2002
|
Bayliss Anti-hypertensive drugs in pregnancy and fetal growth: evidence for 'pharmacological programming' in the first trimester? Hypertens Pregnancy 2002; 21:161-74
|
|
Bergman - Beta-blockers, 2018
|
Bergman Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study. Drug Saf 2018; 41:415-427
|
|
Caton - Beta-blockers, 2009
|
Caton Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63-70
|
|
Cedergren - Beta-blockers, 2002
|
Cedergren Risk factors for cardiovascular malformation--a study based on prospectively collected data. Scand J Work Environ Health 2002; 28:12-7
|
|
Chan - Labetalol, 2010
|
Chan WS Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29:271-83
|
|
Cruickshank - Labetalol, 1990
|
Cruickshank Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:1103
|
|
Cruickshank - Labetalol, 1991
|
Cruickshank Maternal Obstetric Outcome Measures in A Randomised Controlled Study of Labetalol in the Treatment of Hypertension in Pregnancy, Clinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1991, 10:3, 333-344.
|
|
Darcie - Atenolol, 2004
|
Darcie Glycemia in newborns of hypertensive mothers
according to maternal treatment. Rev. Hosp Clin. 2004, 59, 244–250
|
|
Delteil - Beta-blockers, 2024
|
Delteil Beta-blockers and pregnancy - An EFEMERIS study Scientific report. 2024: 1-67.
|
|
Duan - Beta-blockers, 2017
|
Duan ?-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies. JAMA Intern Med 2017; 177:885-887
|
|
Duan - Beta-blockers, 2018
|
Duan Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich) 2018; 20:1603-1609
|
|
Ersboll - Beta-blockers (Controls unexposed, disease free), 2014
|
Ersboll Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG 2014; 121:618-26
|
|
Ersboll - Beta-blockers (Controls unexposed, sick), 2014
|
Ersboll Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG 2014; 121:618-26
|
|
Fidler - Oxprenolol, 1983
|
Fidler Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed) 1983; 286:1927-30
|
|
Fisher - Beta-blockers (Controls unexposed, disease free), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher - Beta-blockers (Controls unexposed, sick), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher a - Beta-blockers, 2018
|
Fisher Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res 2018; 110:1433-1442
|
|
Fisher b - Beta-blockers (Controls unexposed, disease free), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Fisher b - Beta-blockers (Controls unexposed, sick), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Fitton - Beta-blockers (Controls unexposed, disease free), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Fitton - Beta-blockers (Controls unexposed, disease free), 2021
|
Fitton Congenital defects and early childhood outcomes following in-utero exposure to antihypertensive medication. J Hypertens 2021; 39:581-588
|
|
Fitton - Beta-blockers (Controls unexposed, sick), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Fitton - Beta-blockers (Controls unexposed, sick), 2021
|
Fitton Congenital defects and early childhood outcomes following in-utero exposure to antihypertensive medication. J Hypertens 2021; 39:581-588
|
|
Gandjbakhch - Beta-blockers, 2018
|
Gandjbakhch Pregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Int J Cardiol 2018; 258:172-178
|
|
Hoeltzenbein c - Bisoprolol, 2018
|
Hoeltzenbein Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study. J Hypertens 2018; 36:2109-2117
|
|
Ishibashi - Beta-blockers, 2017
|
Ishibashi Arrhythmia risk and ?-blocker therapy in pregnant women with long QT syndrome. Heart 2017; 103:1374-1379
|
|
Kayser - Metoprolol/bisoprolol, 2020
|
Kayser Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens 2020; 38:354-361
|
|
Kubota - Beta-blockers, 2023
|
Kubota Alpha/Beta- and Beta-Blocker Exposure in Pregnancy and the Risk of Neonatal Hypoglycemia and Small for Gestational Age. Circ J 2023; 87:569-577
|
|
Kumar - Beta-blockers, 2020
|
Kumar Impact of Maternal HbA1c Levels <=6% and Race in Nondiabetic Pregnancies on Birthweight and Early Neonatal Hypoglycemia. J Pediatr 2020; 227:121-127.e3
|
|
Lennestal - Beta-blockers, 2009
|
Lennestal Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615-25
|
|
Lieberman - Propranolol, 1978
|
Lieberman The possible adverse effect of propranolol on the fetus in pregnancies complicated by severe hypertension. Br J Obstet Gynaecol 1978; 85:678-83
|
|
Lydakis - Atenolol, 1999
|
Lydakis Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541-7
|
|
Mazkereth - Beta-blockers, 2019
|
Mazkereth Short-Term Neonatal Outcome among Term Infants after In-Utero Exposure to Beta Blockers. Isr Med Assoc J 2019; 21:724-727
|
|
Medveczky - Pindolol, 2004
|
Medveczky The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiol Drug Saf 2004; 13:443-55
|
|
Nakhai-Pour - Beta-blockers, 2010
|
Nakhai-Pour Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89:147-54
|
|
Orbach - Atenolol, 2013
|
Orbach Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013; 208:301.e1-6
|
|
Petersen - Beta-blockers, 2012
|
Petersen Beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012; 2:
|
|
Puho - Metoprolol, 2007
|
Puho Drug treatment during pregnancy and isolated orofacial clefts in hungary. Cleft Palate Craniofac J 2007; 44:194-202
|
|
Puho - Oxprenolol, 2007
|
Puho Drug treatment during pregnancy and isolated orofacial clefts in hungary. Cleft Palate Craniofac J 2007; 44:194-202
|
|
Queisser-Luft - Beta-blockers, 1996
|
Queisser-Luft Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. Am J Med Genet 1996; 63:268-76
|
|
Ray - Beta-blockers, 2001
|
Ray Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth 2001; 1:6
|
|
Rosenfeld - Pindolol, 1986
|
Rosenfeld Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur J Obstet Gynecol Reprod Biol 1986; 22:197-204
|
|
Sibai - Labetalol, 1990
|
Sibai A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960-6; discussion 966-7
|
|
Su - Beta-blockers (Controls unexposed, disease free), 2013
|
Su Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One 2013; 8:e53844
|
|
Su - Beta-blockers (Controls unexposed, sick) , 2013
|
Su Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One 2013; 8:e53844
|
|
Syvanen - Beta-blockers, 2021
|
Syvanen Risk Factors and Prevalence of Limb Deficiencies Associated With Amniotic Band Sequence: A Population-based Case-control Study. J Pediatr Orthop 2021; 41:e94-e97
|
|
Tanaka - Beta-blockers, 2016
|
Tanaka Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease. Circ J 2016; 80:2221-6
|
|
Thewissen - Labetalol (Controls unexposed, disease free), 2017
|
Thewissen Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy. J Matern Fetal Neonatal Med 2017; 30:1533-1538
|
|
Thewissen - Labetalol (Controls unexposed, sick), 2017
|
Thewissen Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy. J Matern Fetal Neonatal Med 2017; 30:1533-1538
|
|
Vaclavik - Beta-blockers, 2024
|
Vaclavik, J. MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022 Int. J. Hypertens. 2024; 42:e10-.
|
|
Van Zutphen - Beta-blockers, 2014
|
Caton Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82:34-40 Van Zutphen AR Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol 2014;123:309-17
|
|
Vasilakis-Scaramozza - Beta-blockers, 2013
|
Vasilakis-Scaramozza Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy 2013; 33:476-82
|
|
Xiang - Labetalol, 2020
|
Xiang Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. Cell Mol Biol (Noisy-le-grand) 2020; 66:9-13
|
|
Yassen - Acebutolol, 1992
|
Yassen [Hemodynamic and renal adaptation of newborn infants of hypertensive mothers treated with acebutolol]. Arch Fr Pediatr 1992; 49:351-5
|
